Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: Prognostic significance of a sialylated MUC1 epitope

International Journal of Oncology

Volumn 27, Issue 5, 2005, Pages 1289-1297

  Baldus, Stephan E ^a   Wienand, Jens R ^a   Werner, Jan P ^a   Landsberg, Stephanie ^a   Drebber, Uta ^a   Hanisch, Franz Georg ^a   Dienes, Hans P ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Breast cancer; Carbohydrate antigens; Immunohistology; Mammary carcinoma; MUC1; MUC2; Mucins; Oligosaccharides; Prognosis

Indexed keywords

ANTIGEN; BETA GALACTOSYL(1 3) N ACETYLGALACTOSAMINE; BETA-GALACTOSYL(1-3)-N-ACETYLGALACTOSAMINE; EPITOPE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; MUC 2 PROTEIN; MUC1 PROTEIN, HUMAN; MUCIN; OLIGOSACCHARIDE; SIALYL LE(A) OLIGOSACCHARIDE; SIALYL-LE(A) OLIGOSACCHARIDE; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENETICS; GLYCOSYLATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; EPITOPES; FEMALE; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUCINS; OLIGOSACCHARIDES; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 33644639606     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.5.1289     Document Type: Article

References (54)

1. Taylor-Papadimitriou J, Burchell J, Miles DW and Dalziel M: MUC1 and cancer. Biochim Biophys Acta 1455: 301-313, 1999.
2. Hanisch FG and Muller S: MUC1: the polymorphic appearance of a human mucin. Glycobiology 10: 439-449, 2000.
3. Baldus SE, Engelmann K and Hanisch FG: MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41: 189-231, 2004.
4. Gendler S J, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN and Wilson D: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265: 15286-15293, 1990.
5. Lan MS, Batra SK, Qi WN, Metzgar RS and Hollingsworth MA: Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem 265: 15294-15299, 1990.
6. Ligtenberg MJ, Vos HL, Gennissen AM and Hilkens J: Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 265: 5573-5578,1990.
7. Wreschner DH, Hareuveni M, Tsarfaty I, Smorodinsky N, Horev J, Zaretsky J, Kotkes P, Weiss M, Lathe R, Dion A, et al Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. Eur J Biochem 189:463-473,1990.
8. Engelmann K, Baldus SE and Hanisch FG: Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J Biol Chem 276: 27764-27769,2001.
9. Ellis IO, Hinton CP, MacNay J, Elston CW, Robins A, Owainati AA, Blarney RW, Baldwin RW and Ferry B: Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J (Clin Res Ed) 290: 881-883, 1985.
10. Ellis IO, Bell J, Todd JM, Williams M, Dowle C, Robins AR, Elston CW, Blarney RW and Baldwin RW: Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. Br J Cancer 56: 295-299,1987.
11. Walker RA: Assessment of milk fat globule membrane antibodies and lectins as markers of short-term prognosis in breast cancer. Br J Cancer 62: 462-466,1990.
12. Hayes DF, Mesa-Tejada R, Papsidero LD, Croghan GA, Korzun AH, Norton L, Wood W, Strauchen JA, Grimes M, Weiss RB, et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol 9: 1113-1123, 1991.
13. Byrne J, Horgan PG, England S, Callaghan J and Given HF: An evaluation of the usefulness of primary tumour expression of MCA and CA15-3 as prognostic indicators in breast carcinoma. Eur J Surg Oncol 18: 230-234, 1992.
14. McGuckin MA, Walsh MD, Hohn BG, Ward BG and Wright RG: Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 26: 432-439, 1995.
15. Luna-More S, Rius F, Weil B, Jimenez A, Bautista MD and Perez-Mellado A: EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas. Pathol Res Pract 197: 419-425,2001.
16. Rahn JJ, Dabbagh L, Pasdar M and Hugh JC: The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91: 1973-1982, 2001.
17. Ceriani RL, Chan CM, Baratta FS, Ozzello L, De Rosa CM and Habif DV: Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int J Cancer 51: 343-354, 1992.
18. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson K, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB, Hilgers J, et al: Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, CA, November 17-23, 1996. Tumour Biol 19 (Suppl. 1): 1-20,1998.
19. Walsh MD, McGuckin MA, Devine PL, Hohn BG and Wright RG: Expression of MUC2 epithelial mucin in breast carcinoma. J Clin Pathol 46: 922-925, 1993.
20. Hanski C, Hofmeier M, Schmitt-Graff A, Riede E, Hanski ML, Borchard F, Sieber E, Niedobitek F, Foss HD, Stein H and Riecken EO: Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol 182: 385-391,1997.
21. Chu JS and Chang KJ: Mucin expression in mucinous carcinoma and other invasive carcinomas of the breast. Cancer Lett 142: 121-127,1999.
22. Matsukita S, Nomoto M, Kitajima S, Tanaka S, Goto M, Irimura T, Kim YS, Sato E and Yonezawa S: Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma. Histopathology 42: 26-36, 2003.
23. Hanisch FG: O-glycosylation of the mucin type. Biol Chem 382:143-149,2001.
24. Wang BL, Springer GF and Carlstedt SC: Quantitative computerized image analysis of Tn and T (Thomsen-Friedenreich) epitopes in prognostication of human breast carcinoma. J Histochem Cytochem 45: 1393-1400,1997.
25. Yamaguchi A, Ding K, Maehara M, Goi T and Nakagawara G: Expression of nm23-H1 gene and Sialyl Lewis X antigen in breast cancer. Oncology 55: 357-362,1998.
26. Nakagoe T, Fukushima K, Itoyanagi N, Ikuta Y, Oka T, Nagayasu T, Ayabe H, Hara S, Ishikawa H and Minami H: Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 128: 257-264,2002.
27. Hanisch FG: Specificity clusters of MUC1-reactive mouse monoclonal antibodies. Tumour Biol 19 (Suppl. 1): 111-117, 1998.
28. Yonezawa S and Sato E: Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 47: 813-830, 1997.
29. Yonezawa S, Taira M, Osako M, Kubo M, Tanaka S, Sakoda K, Takao S, Aiko T, Yamamoto M, Irimura T, Kim YS and Sato E: MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathol Int 48: 319-322, 1998.
30. Fujita K, Denda K, Yamamoto M, Matsumoto T, Fujime M and Irimura T: Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br J Cancer 80: 301-308,1999.
31. Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS and Sato E: Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 30: 1347-1355, 1999.
32. Masaki Y, Oka M, Ogura Y, Ueno T, Nishihara K, Tangoku A, Takahashi M, Yamamoto M and Irimura T: Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma. Hepatogastroenterology 46:2240-2245,1999.
33. Hanisch FG, Stadie TR, Deutzmann F and Peter-Katalinic J: MUC1 glycoforms in breast cancer-cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation. Eur J Biochem 236: 318-327, 1996.
34. Muller S, Alving K, Peter-Katalinic J, Zachara N, Gooley AA and Hanisch FG: High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. J Biol Chem 274: 18165-18172,1999.
35. Hanisch FG, Uhlenbruck G, Peter-Katalinic J, Egge H, Dabrowski J and Dabrowski U: Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Gal beta(1-4)GlcNAc beta(1-6) repeating units. J Biol Chem 264: 872-883, 1989.
36. Hanisch FG, Peter-Katalinic J, Egge H, Dabrowski U and Uhlenbruck G: Structures of acidic O-linked polylactosaminoglycans on human skim milk mucins. Glycoconj J 7: 525-543, 1990.
37. Lloyd KO, Burchell J, Kudryashov V, Yin BW and Taylor- Papadimitriou J: Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 271: 33325-33334, 1996.
38. Kemperman H, Wijnands Y, Wesseling J, Niessen CM, Sonnenberg A and Roos E: The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction. J Cell Biol 127: 2071-2080, 1994.
39. Wesseling J, van der Valk SW, Vos HE, Sonnenberg A and Hilkens J: Episialin (MUC1) overexpression inhibits integrinmediated cell adhesion to extracellular matrix components. J Cell Biol 129: 255-265, 1995.
40. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G and Hugh JC: The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 56: 4244-4249,1996.
41. Yamamoto M, Bharti A, Li Y and Kufe D: Interaction of the DF3/MUC1 breast carcinoma-associated antigen and betacatenin in cell adhesion. J Biol Chem 272: 12492-12494,1997.
42. Wen Y, Caffrey TC, Wheelock MJ, Johnson KR and Hollingsworth MA: Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 278: 38029-38039, 2003.
43. Huang L, Ren J, Chen D, Li Y, Kharbanda S and Kufe D: MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther 2: 702-706,2003.
44. Li Y, Liu D, Chen D, Kharbanda S and Kufe D: Human DF3/ MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 22: 6107-6110,2003.
45. Hilkens J, Kroezen V, Bonfrer JM, De Jong-Bakker M and Bruning PF: MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res 46: 2582-2587, 1986.
46. Kotera Y, Fontenot JD, Pecher G, Metzgar RS and Finn OJ: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54: 2856-2860,1994.
47. Agrawal B, Reddish MA, Krantz MJ and Longenecker BM: Does pregnancy immunize against breast cancer? Cancer Res 55:2257-2261,1995.
48. Croce MV, Isla-Larrain MT, Capafons A, Price MR and Segal- Eiras A: Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat69: 1-11,2001.
49. Croce MV, Isla-Larrain MT, Price MR and Segal-Eiras A: Detection of circulating mammary mucin (Mucl) and MUC1 immune complexes (Mucl-CIC) in healthy women. Int J Biol Markers 16: 112-120,2001.
50. Agrawal B, Reddish MA and Longenecker BM: In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 157: 2089-2095,1996.
51. Von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO and Hilgers J: Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (Ga1NAc) peptides. Int J Cancer 86: 702-712, 2000.
52. Gendler SJ: MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6: 339-353, 2001.
53. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D and Smith M: MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7: 209-221, 2002.
54. Karsten U, Diotel C, Klich G, Paulsen H, Goletz S, Muller S and Hanisch FG: Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by sitespecific glycosylation. Cancer Res 58: 2541-2549,1998.